Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B

Robert Perrillo, Maria Buti, Francois Durand, Michael Charlton, Adrian Gadano, Guido Cantisani, Che‐Chuan Loong, Kimberly Brown, Wenhua Hu, Juan Carlos Lopez‐Talavera, Cyril Llamoso – 21 June 2013 – For patients undergoing liver transplantation (LT) for hepatitis B virus (HBV)–related liver disease, the current standard of care for preventing reinfection of the allograft is nucleoside analogue therapy combined with hepatitis B immune globulin (HBIG).

Living related liver transplantation for hepatitis B–related liver disease without hepatitis B immune globulin prophylaxis

Manav Wadhawan, Subash Gupta, Neerav Goyal, Sunil Taneja, Ajay Kumar – 21 June 2013 – Hepatitis B immune globulin (HBIG) is routinely used in liver transplantation for hepatitis B virus (HBV)–related liver disease. With potent oral antivirals, HBIG may not be required. We conducted a prospective trial to evaluate living related liver transplantation (LRLT) without HBIG. Eighty‐nine patients with HBV‐related liver disease underwent LRLT between January 2005 and January 2012. All donors were vaccinated with the HBV vaccine.

Subscribe to